Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Inflammatory Bowel Diseases

  Free Subscription


30.09.2019

1 Clin Gastroenterol Hepatol
2 Gastroenterology
2 Gut
2 J Crohns Colitis
3 N Engl J Med
1 PLoS One
2 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Clin Gastroenterol Hepatol

  1. MA C, Sandborn WJ, D'Haens GR, Zou G, et al
    Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Sep 20. pii: S1542-3565(19)31027.
    PubMed     Text format     Abstract available


    Gastroenterology

  2. XIAO L, Li XX, Chung HK, Kalakonda S, et al
    RNA-Binding Protein HuR Regulates Paneth Cell Function by Altering Membrane Localization of TLR2 via Post-transcriptional Control of CNPY3.
    Gastroenterology. 2019;157:731-743.
    PubMed     Text format     Abstract available

  3. PIOVANI D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, et al
    Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses.
    Gastroenterology. 2019;157:647-659.
    PubMed     Text format     Abstract available


    Gut

  4. PARKES M
    IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis.
    Gut. 2019;68:1537-1540.
    PubMed     Text format    

  5. STJARNGRIM J, Ekbom A, Hammar U, Hultcrantz R, et al
    Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population?
    Gut. 2018 Dec 15. pii: gutjnl-2018-316651. doi: 10.1136/gutjnl-2018-316651.
    PubMed     Text format     Abstract available


    J Crohns Colitis

  6. CHAPUY L, Bsat M, Rubio M, Harvey F, et al
    Transcriptomic analysis and High dimensional phenotypic mapping of mononuclear phagocytes in mesenteric lymph nodes reveal differences between ulcerative colitis and Crohn's disease.
    J Crohns Colitis. 2019 Sep 21. pii: 5572419. doi: 10.1093.
    PubMed     Text format     Abstract available

  7. ADAMINA M, Gerasimidis K, Sigall-Boneh R, Zmora O, et al
    Perioperative dietary therapy in inflammatory bowel disease.
    J Crohns Colitis. 2019 Sep 24. pii: 5573284. doi: 10.1093.
    PubMed     Text format     Abstract available


    N Engl J Med

  8. SANDS BE, Sandborn WJ, Panaccione R, O'Brien CD, et al
    Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    N Engl J Med. 2019;381:1201-1214.
    PubMed     Text format     Abstract available

  9. SANDS BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, et al
    Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    N Engl J Med. 2019;381:1215-1226.
    PubMed     Text format     Abstract available

  10. FARRELL RJ
    Biologics beyond Anti-TNF Agents for Ulcerative Colitis - Efficacy, Safety, and Cost?
    N Engl J Med. 2019;381:1279-1281.
    PubMed     Text format    


    PLoS One

  11. THOMAS T, Chandan JS, Li VSW, Lai CY, et al
    Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts.
    PLoS One. 2019;14:e0221961.
    PubMed     Text format     Abstract available


    Scand J Gastroenterol

  12. RIBALDONE DG, Vernero M, Parisi S, Ditto MC, et al
    Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients.
    Scand J Gastroenterol. 2019 Sep 24:1-4. doi: 10.1080/00365521.2019.1668052.
    PubMed     Text format     Abstract available

  13. BODINI G, Demarzo MG, Saracco M, Coppo C, et al
    High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Sep 25:1-6. doi: 10.1080/00365521.2019.1666914.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: